Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
Trial ID or NCT#
Status
Purpose
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Official Title
An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant
Eligibility Criteria
- - active chronic GvHD
- * ANC \> 1000/mm\^3* therapeutic cyclosporine
- - uncontrolled systemic infection* elevated serum creatinine
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
BMT Referrals
6507230822
View on ClinicalTrials.gov